DOCSLIB.ORG

Pivalone Tixocortol Pivalate Nasal Suspension

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pivalone Tixocortol Pivalate Nasal Suspension Pivalone Tixocortol Pivalate Nasal Suspension CAREFULLY SHAKE THE BOTTLE BEFORE USE COMPOSITION Tixocortol pivalate…………………………………………………………………… 1.000 g N-cetylpyridinium chloride……………………………………………………………0.020 g Excipient to………………………………………………………………………………100 g Bottle containing 10 ml of suspension. PHARMACEUTICAL FORM 1% tixocortol pivalate nasal suspension (10 ml nasal spray bottle) THERAPEUTIC PROPERTIES Tixocortol pivalate: local anti-inflammatory corticoid devoid of systemic effects. INDICATIONS Allergic rhinitis Seasonal rhinitis Acute congestive rhinitis Chronic congestive rhinitis Vasomotor rhinitis CONTRAINDICATIONS Antecedent allergy to the product. Epistaxis Existence of viral or fungal infections during treatment and existence of significant local superinfection DOSAGE AND ADMINISTRATION 1 to 2 pulverizations in each nostril 2 to 4 times a day. Do not exceed the prescribed dose. SPECIAL WARNINGS AND PRECAUTIONS FOR USE To be used after carefully blowing or cleaning the nose. In the event of systemic signs of bacterial infection, treatment with a systemic antibiotic must be considered. Events of epidural lipomatosis, central serous chorioretinopathy and pheochromocytoma crisis have been associated with systemic administration of corticosteroids. Long-term administration of inhaled or topical corticosteroid formulations may also be associated with these potential systemic effects. Page 1 of 6 Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids. EFFECTS ON ABILITY TO DRIVE AND USE MACHINES This medication would not be expected to impair the ability to drive or use machines. SIDE EFFECTS ADRs by SOC and CIOMS frequency category listed in order of decreasing medical seriousness within each frequency category and SOC System Very Common Uncommon Rare Very Frequency Organ Class Common ≥1/100 ≥1/1,000 to ≥ Rare Not Known ≥1/10 to <1/10 <1/100 1/10,000 <1/10,0 (cannot be to 00 estimated <1/1,000 from the available data) Immune Hypersensitivity* system disorders Respiratory, Nasal dryness*, thoracic and Rhinalgia†, mediastinal Epistaxis disorders Skin and Angioedema* subcutaneous tissue disorders Eye disorder Vision, blurred (see section Special Warnings and Precautions for Use) General Face oedema* disorders and administration site conditions * These reactions regress at discontinuation of the treatment. † May occur at the start of treatment. FERTILITY, PREGNANCY AND LACTATION In an oral fertility and developmental toxicity study in rats, there was no effect on fertility and tixocortol was not teratogenic, although it was shown to be teratogenic in a study in rabbits (see section Preclinical safety data). Since adequate human reproductive studies have not been done with tixocortol, this medicinal product should be used during pregnancy only after a careful assessment of the benefit risk ratio to the mother and fetus/child. Avoid using the product during pregnancy unless potential benefit outweighs risk. Page 2 of 6 It is not known whether the drug is excreted in human milk. Breast-feeding should be avoided during treatment. OVERDOSE No cases of tixocortol overdose are currently known. ABUSE AND DEPENDENCE Tixocortol has not shown the potential for drug abuse or dependence. PHARMACOLOGICAL PROPERTIES Pharmacodynamic properties Local corticosteroid: anti-allergic, anti-inflammatory. Tixocortol pivalate has the local efficacy of reference corticosteroids but is devoid of significant corticosteroid activity remote from the site of application in humans. Administration of 130 times the daily therapeutic dose in humans does not lead to any systemic glucocorticoid effects. The PIVALONE 1% nasal suspension dosage form respects nasal drainage by the ciliary beats of the pituitary mucous membranes. Pharmacokinetic properties Studies conducted in animals and humans have demonstrated the extremely rapid metabolism of tixocortol pivalate, explaining the absence of any significant systemic corticosteroid effects in humans. Tixocortol pivalate is well absorbed by the oral route; however, even after oral administration of a very large dose (2 g), only inactive metabolites, devoid of any glucocorticoid action, are found in the general circulation. This is due to extremely rapid degradation of tixocortol pivalate, mainly hepatic. Preclinical safety data General toxicity studies in rats and nonhuman primates did not identify any special hazards. In an oral fertility and developmental toxicity study in rats, there was no effect on fertility. Prenatal developmental toxicity consisted of slight increases in post implantation loss and reduced fetal weight, and tixocortol was not teratogenic. There were no adverse effects on postnatal development. In an embryo fetal development study, tixocortol pivalate was administered daily via oral gavage to timed pregnant rabbits at doses up to 360 mg/kg/day from gestation day 6 through 18. At doses ≥120 mg/kg/day, at which maternal toxicity was observed, there were reduced fetal body weights and increases in the incidence of major malformations (hydrocephaly, cleft palate, and skeletal malformations). Increased post implantation loss, lower litter sizes, and skeletal anomalies were also observed at 360 mg/kg/day. On a mg/kg basis, the doses administered in this study greatly exceeded those in humans receiving the topically administered product. Page 3 of 6 Tixocortol was not clastogenic in human lymphocytes and a negative response was obtained in the in vivo micronucleus assay in mice. Tixocortol did not show any carcinogenic potential in 2-year oral gavage studies in rats dosed up to 250 mg/kg/day and in mice dosed up to 100 mg/kg/day. INCOMPATIBILITIES AND INTERACTIONS No known incompatibilities and drugs interactions have been reported. STORAGE AND STABILITY Shelf-life: 3 years Store at or below 30°C NATURE AND CONTENTS OF CONTAINER Plastic spray bottles SPECIAL PRECAUTIONS FOR DISPOSAL AND OTHER HANDLING No special requirements. Page 4 of 6 HOW TO USE 1. Carefully shake the bottle. Remove the protective cap. 2. Press several times to start the pulverization process. 3. Insert the long end of the bottle vertically into the nostril and press firmly. PRODUCT OWNER Pfizer Inc. 235 East 42nd Street Page 5 of 6 New York 10017, US PIV-SIN-0919/0 Date of Last Revision: September 2019 Page 6 of 6.
Load more

Recommended publications
  • Steroid Use in Prednisone Allergy Abby Shuck, Pharmd Candidate
    Steroid Use in Prednisone Allergy Abby Shuck, PharmD candidate 2015 University of Findlay If a patient has an allergy to prednisone and methylprednisolone, what (if any) other corticosteroid can the patient use to avoid an allergic reaction? Corticosteroids very rarely cause allergic reactions in patients that receive them. Since corticosteroids are typically used to treat severe allergic reactions and anaphylaxis, it seems unlikely that these drugs could actually induce an allergic reaction of their own. However, between 0.5-5% of people have reported any sort of reaction to a corticosteroid that they have received.1 Corticosteroids can cause anything from minor skin irritations to full blown anaphylactic shock. Worsening of allergic symptoms during corticosteroid treatment may not always mean that the patient has failed treatment, although it may appear to be so.2,3 There are essentially four classes of corticosteroids: Class A, hydrocortisone-type, Class B, triamcinolone acetonide type, Class C, betamethasone type, and Class D, hydrocortisone-17-butyrate and clobetasone-17-butyrate type. Major* corticosteroids in Class A include cortisone, hydrocortisone, methylprednisolone, prednisolone, and prednisone. Major* corticosteroids in Class B include budesonide, fluocinolone, and triamcinolone. Major* corticosteroids in Class C include beclomethasone and dexamethasone. Finally, major* corticosteroids in Class D include betamethasone, fluticasone, and mometasone.4,5 Class D was later subdivided into Class D1 and D2 depending on the presence or 5,6 absence of a C16 methyl substitution and/or halogenation on C9 of the steroid B-ring. It is often hard to determine what exactly a patient is allergic to if they experience a reaction to a corticosteroid.
    [Show full text]
  • Contact Dermatitis to Medications and Skin Products
    Clinical Reviews in Allergy & Immunology (2019) 56:41–59 https://doi.org/10.1007/s12016-018-8705-0 Contact Dermatitis to Medications and Skin Products Henry L. Nguyen1 & James A. Yiannias2 Published online: 25 August 2018 # Springer Science+Business Media, LLC, part of Springer Nature 2018 Abstract Consumer products and topical medications today contain many allergens that can cause a reaction on the skin known as allergic contact dermatitis. This review looks at various allergens in these products and reports current allergic contact dermatitis incidence and trends in North America, Europe, and Asia. First, medication contact allergy to corticosteroids will be discussed along with its five structural classes (A, B, C, D1, D2) and their steroid test compounds (tixocortol-21-pivalate, triamcinolone acetonide, budesonide, clobetasol-17-propionate, hydrocortisone-17-butyrate). Cross-reactivities between the steroid classes will also be examined. Next, estrogen and testosterone transdermal therapeutic systems, local anesthetic (benzocaine, lidocaine, pramoxine, dyclonine) antihistamines (piperazine, ethanolamine, propylamine, phenothiazine, piperidine, and pyrrolidine), top- ical antibiotics (neomycin, spectinomycin, bacitracin, mupirocin), and sunscreen are evaluated for their potential to cause contact dermatitis and cross-reactivities. Finally, we examine the ingredients in the excipients of these products, such as the formaldehyde releasers (quaternium-15, 2-bromo-2-nitropropane-1,3 diol, diazolidinyl urea, imidazolidinyl urea, DMDM hydantoin), the non- formaldehyde releasers (isothiazolinones, parabens, methyldibromo glutaronitrile, iodopropynyl butylcarbamate, and thimero- sal), fragrance mixes, and Myroxylon pereirae (Balsam of Peru) for contact allergy incidence and prevalence. Furthermore, strategies, recommendations, and two online tools (SkinSAFE and the Contact Allergen Management Program) on how to avoid these allergens in commercial skin care products will be discussed at the end.
    [Show full text]
  • Rectal Corticosteroids Versus Alternative Treatments in Ulcerative Colitis: a Meta-Analysis Gut: First Published As 10.1136/Gut.40.6.775 on 1 June 1997
    Gut 1997; 40: 775-781 775 Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis Gut: first published as 10.1136/gut.40.6.775 on 1 June 1997. Downloaded from J K Marshall, E J Irvine Abstract medication consistently to the splenic Background-Clear strategies to optimise flexure,49 and a larger volume seems to allow the use of corticosteroids in ulcerative more proximal delivery.10 11 Rectal foam dis- colitis are lacking. seminates medication to the rectum and distal Aim-A meta-analysis was undertaken to descending colon,'2-16 whereas suppositories examine critically the role of rectal corti- coat only the rectum.'7 18 costeroids in the management of active Although studies of rectally administered distal ulcerative colitis. corticosteroids have reported fewer systemic Methods-AJl reported randomised con- adverse effects than with oral preparations, trolled trials were retrieved by searching plasma concentrations of prednisolone were the Medline and EMBASE databases and similar after administration of identical oral or the bibliographies of relevant studies. rectal doses.'9 20 Suppression of the hypo- Trials which met inclusion criteria were thalamic-pituitary-adrenal axis in association assessed for scientific rigour. Data were with rectal therapy has also been shown.2' 26 extracted by two independent observers Newer topically active corticosteroids such according to predetermined criteria. as tixocortol, beclomethasone, prednisolone Results-Of 83 trials retrieved, 33 met metasulphabenzoate, and budesonide, with inclusion criteria. Pooled odds ratios restricted absorption or rapid hepatic metab- (POR) showed conventional rectal corti- olism have been developed to reduce the costeroids and rectal budesonide to be adverse effects associated with conventional clearly superior to placebo.
    [Show full text]
  • Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1
    vr_meds_ex01_3b_0825s Coding Manual Supplement MEDNAME OTHER_CODE ATC_CODE SYSTEM THER_GP PHRM_GP CHEM_GP SODIUM FLUORIDE A12CD01 A01AA01 A A01 A01A A01AA SODIUM MONOFLUOROPHOSPHATE A12CD02 A01AA02 A A01 A01A A01AA HYDROGEN PEROXIDE D08AX01 A01AB02 A A01 A01A A01AB HYDROGEN PEROXIDE S02AA06 A01AB02 A A01 A01A A01AB CHLORHEXIDINE B05CA02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D08AC02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D09AA12 A01AB03 A A01 A01A A01AB CHLORHEXIDINE R02AA05 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S01AX09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S02AA09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S03AA04 A01AB03 A A01 A01A A01AB AMPHOTERICIN B A07AA07 A01AB04 A A01 A01A A01AB AMPHOTERICIN B G01AA03 A01AB04 A A01 A01A A01AB AMPHOTERICIN B J02AA01 A01AB04 A A01 A01A A01AB POLYNOXYLIN D01AE05 A01AB05 A A01 A01A A01AB OXYQUINOLINE D08AH03 A01AB07 A A01 A01A A01AB OXYQUINOLINE G01AC30 A01AB07 A A01 A01A A01AB OXYQUINOLINE R02AA14 A01AB07 A A01 A01A A01AB NEOMYCIN A07AA01 A01AB08 A A01 A01A A01AB NEOMYCIN B05CA09 A01AB08 A A01 A01A A01AB NEOMYCIN D06AX04 A01AB08 A A01 A01A A01AB NEOMYCIN J01GB05 A01AB08 A A01 A01A A01AB NEOMYCIN R02AB01 A01AB08 A A01 A01A A01AB NEOMYCIN S01AA03 A01AB08 A A01 A01A A01AB NEOMYCIN S02AA07 A01AB08 A A01 A01A A01AB NEOMYCIN S03AA01 A01AB08 A A01 A01A A01AB MICONAZOLE A07AC01 A01AB09 A A01 A01A A01AB MICONAZOLE D01AC02 A01AB09 A A01 A01A A01AB MICONAZOLE G01AF04 A01AB09 A A01 A01A A01AB MICONAZOLE J02AB01 A01AB09 A A01 A01A A01AB MICONAZOLE S02AA13 A01AB09 A A01 A01A A01AB NATAMYCIN A07AA03 A01AB10 A A01
    [Show full text]
  • Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs
    Specific Drugs Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs Chief Editors: Ana Dioun Broyles, MD, Aleena Banerji, MD, and Mariana Castells, MD, PhD Ana Dioun Broyles, MDa, Aleena Banerji, MDb, Sara Barmettler, MDc, Catherine M. Biggs, MDd, Kimberly Blumenthal, MDe, Patrick J. Brennan, MD, PhDf, Rebecca G. Breslow, MDg, Knut Brockow, MDh, Kathleen M. Buchheit, MDi, Katherine N. Cahill, MDj, Josefina Cernadas, MD, iPhDk, Anca Mirela Chiriac, MDl, Elena Crestani, MD, MSm, Pascal Demoly, MD, PhDn, Pascale Dewachter, MD, PhDo, Meredith Dilley, MDp, Jocelyn R. Farmer, MD, PhDq, Dinah Foer, MDr, Ari J. Fried, MDs, Sarah L. Garon, MDt, Matthew P. Giannetti, MDu, David L. Hepner, MD, MPHv, David I. Hong, MDw, Joyce T. Hsu, MDx, Parul H. Kothari, MDy, Timothy Kyin, MDz, Timothy Lax, MDaa, Min Jung Lee, MDbb, Kathleen Lee-Sarwar, MD, MScc, Anne Liu, MDdd, Stephanie Logsdon, MDee, Margee Louisias, MD, MPHff, Andrew MacGinnitie, MD, PhDgg, Michelle Maciag, MDhh, Samantha Minnicozzi, MDii, Allison E. Norton, MDjj, Iris M. Otani, MDkk, Miguel Park, MDll, Sarita Patil, MDmm, Elizabeth J. Phillips, MDnn, Matthieu Picard, MDoo, Craig D. Platt, MD, PhDpp, Rima Rachid, MDqq, Tito Rodriguez, MDrr, Antonino Romano, MDss, Cosby A. Stone, Jr., MD, MPHtt, Maria Jose Torres, MD, PhDuu, Miriam Verdú,MDvv, Alberta L. Wang, MDww, Paige Wickner, MDxx, Anna R. Wolfson, MDyy, Johnson T. Wong, MDzz, Christina Yee, MD, PhDaaa, Joseph Zhou, MD, PhDbbb, and Mariana Castells, MD, PhDccc Boston, Mass; Vancouver and Montreal,
    [Show full text]
  • Wo 2008/127291 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date PCT (10) International Publication Number 23 October 2008 (23.10.2008) WO 2008/127291 A2 (51) International Patent Classification: Jeffrey, J. [US/US]; 106 Glenview Drive, Los Alamos, GOlN 33/53 (2006.01) GOlN 33/68 (2006.01) NM 87544 (US). HARRIS, Michael, N. [US/US]; 295 GOlN 21/76 (2006.01) GOlN 23/223 (2006.01) Kilby Avenue, Los Alamos, NM 87544 (US). BURRELL, Anthony, K. [NZ/US]; 2431 Canyon Glen, Los Alamos, (21) International Application Number: NM 87544 (US). PCT/US2007/021888 (74) Agents: COTTRELL, Bruce, H. et al.; Los Alamos (22) International Filing Date: 10 October 2007 (10.10.2007) National Laboratory, LGTP, MS A187, Los Alamos, NM 87545 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, AT,AU, AZ, BA, BB, BG, BH, BR, BW, BY,BZ, CA, CH, (30) Priority Data: CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, 60/850,594 10 October 2006 (10.10.2006) US ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, (71) Applicants (for all designated States except US): LOS LR, LS, LT, LU, LY,MA, MD, ME, MG, MK, MN, MW, ALAMOS NATIONAL SECURITY,LLC [US/US]; Los MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, Alamos National Laboratory, Lc/ip, Ms A187, Los Alamos, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, NM 87545 (US).
    [Show full text]
  • Tixocortol, Chlorhexidine Gluconate / Tixocortol Pivalate, the Scientific Conclusions Are As Follows: Cumulatively, There Were 18 Non-Serious Medication Errors
    Annex I Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s) 1 Scientific conclusions Taking into account the PRAC Assessment Report on the PSUR(s) for tixocortol, chlorhexidine gluconate / tixocortol pivalate, the scientific conclusions are as follows: Cumulatively, there were 18 non-serious medication errors. Respectively, three cases of incorrect route of drug administration were identified during the reporting period and 9 cases cumulatively, two of whom were paediatric patients. For these cases, parents administrated nasal drops of tixocortol, chlorhexidine gluconate / tixocortol pivalate to the wrong administration site (eyes or throat). Based on the information reviewed in this PSUR, PRAC considered that sections 1 and 3 of the patient leaflet should be amended to better reflect the correct administration route of tixocortol, chlorhexidine gluconate / tixocortol pivalate for intranasal use in the product information. Therefore, in view of the data presented in the reviewed PSUR(s), the PRAC considered that changes to the product information of medicinal products containing tixocortol, chlorhexidine gluconate / tixocortol pivalate were warranted. The CMDh agrees with the scientific conclusions made by the PRAC. Grounds for the variation to the terms of the Marketing Authorisation(s) On the basis of the scientific conclusions for tixocortol, chlorhexidine gluconate / tixocortol pivalate the CMDh is of the opinion that the benefit-risk balance of the medicinal product(s) containing tixocortol, chlorhexidine gluconate / tixocortol pivalate is unchanged subject to the proposed changes to the product information. The CMDh reaches the position that the marketing authorisation(s) of products in the scope of this single PSUR assessment should be varied.
    [Show full text]
  • Intranasal Corticosteroid
    ReviewArticle Intranasal Corticosteroid Prapaporn Pornsuriyasak, M.D.*, Paraya Assanasen, M.D.** *Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok 10400, **Department of Otorhinolaryngology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand. Siriraj Med J 2008;60:90-95 E-journal: http://www.sirirajmedj.com apidly metabolized intranasal corticosteroid (INS), elastase, and plasminogen activator. Furthermore, lympho- with high topical potency and low systemic bioacti- cyte proliferation and delayed type hypersensitivity are R vity, was introduced for perennial rhinitis in 1974 also inhibited by corticosteroids in vitro. and found to be as effective as corticosteroids admini- The role of corticosteroids in the management of stered systemically.These second-generation INSs allergic rhinitis is influenced by their effect on the inflam- include beclomethasone dipropionate (BDP), budesonide matory cells and chemical mediators that are released in (BUD), flunisolide (FLU), fluticasone propionate (FP), the early- and late-phase allergic responses. The early- triamcinolone acetonide (TAA), mometasone furoate (MF), phase allergic response is characterized by an initial period and fluticasone furoate (FF). Although these INSs represent of sensitization to a specific allergen. Subsequent exposure improvements relative to earlier topical corticos-teroids, to the inciting allergen causes cross-linking of IgE antibodies they do vary from one to the other in potency and systemic located on the surface of mast cells residing in the nasal bioactivity. For example, MF is equal in potency to FP mucosa, which results in mast cell degranulation and the and is considered to be the most potent INS to date and release of various chemical mediators, such as histamine.
    [Show full text]
  • NA61: Tixocortol-21-Pivalate
    the art and science of smart patch testing® NA61: Tixocortol-21-Pivalate CAS#: 55560-96-8 Patient Information What are some products that may contain tixocortol-21-pivalate? Your patch test result indicates that you have a contact allergy to tixocortol-21- • Medications: pivalate. This contact allergy may cause your skin to react when it is exposed to – Creams this substance although it may take several days for the symptoms to appear. – Drops Typical symptoms include redness, swelling, itching, and fluid-filled blisters. – Lotions – Nasal sprays Where is tixocortol-21-pivalate found? – Ointments – Powders Tixocortol-21-pivalate is an anti-inflammatory topical corticosteroid used in – Rectal suspensions the treatment of rhinitis (as a nasal suspension or aerosols), pharyngitis (as • You May Also React to Products That Contain: lozenges), ulcerative colitis (as enema or rectal solution), and oral, inflammatory – Amcinonide conditions (as a suspension or a powder). It is also the principle screening – Budesonide substance for contact allergies to class A steroids. – Cloprednol – Desonide How can you avoid contact with tixocortol-21-pivalate? – Fludrocortisone acetate – Fluocinolone acetonide Avoid products that list any of the following names in the ingredients: – Fluocinonide • Tixocortol 21-pivalate – Flurandrenolide • Tixocortol pivalate – Halcinonide • 11beta,17-Dihydroxy-21-mercaptopregn-4-ene-3,20-dione 21-pivalate – Hydrocortisone • EINECS 259-706-4 – Hydrocortisone 17-butyrate – Hydrocortisone acetate • JO 1016 – Hydrocortisone
    [Show full text]
  • Chemotechnique Patch Test Products & Reference Manual
    Patch Test Products & Reference Manual 2018 7 Patch Test Products & Reference Manual 2018 DISTRIBUTOR MB Diagnostics AB Chemotechnique ©2017 Chemotechnique MB Diagnostics AB ©2017 Chemotechnique MB Diagnostics rev 20171128 Chemotechnique MB Diagnostics AB Modemgatan 9 | SE-235 39 | Vellinge | Sweden Tel +46 40 466 077 | www.chemotechnique.se President’s message With 2017 coming to an end, I look back at the past year with a sense of fulfillment. I reflect on the challenges overcome, the accomplishments achieved and the advancements made in the field of contact allergy. Entering 2018, our full hapten range is registered as pharmaceuticals in Canada following a lengthy regulatory process. The approved registration, the first in history, is a testament to the superior quality of the Chemotechnique products. This accomplishment has been achieved through the tireless work performed by our laboratory staff and from our North American distributor Dormer Laboratories and their consultants. I take this opportunity to extend my appreciation not only to the people involved but to all people fighting to overcome varying regulatory hurdles that are being imposed onto Patch Testing around the world, thereby limiting its beneficial expansion. The notion that an increasing number of patients previously undiagnosed are now experiencing an enhanced quality of life through the diagnosis of contact allergy assures me that Patch Testing remains as relevant as ever before, and I am of the firm belief that Patch Testing is, and will continue to be, a procedure
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2018 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Patch-Testing with Serial Dilutions of Tixocortol Pivalate and Potential Cross-Reactive Substances
    Acta Derm Venereol 2000; 80: 33±38 Patch-testing with Serial Dilutions of Tixocortol Pivalate and Potential Cross-reactive Substances MARLE NE ISAKSSON1, MAGNUS BRUZE1, AN GOOSSENS2 and JEAN-PIERRE LEPOITTEVIN3 1Department of Occupational and Environmental Dermatology, MalmoÈ University Hospital, MalmoÈ, Sweden, 2Department of Dermatology, University Hospital, Katholieke Universiteit Leuven, Leuven, Belgium and 3Laboratoire de Dermatochimie associe au CNRS, Universite Louis-Pasteur, Clinique Dermatologique, Strasbourg, France Of patch-tested patients with dermatitis, 4 ± 5% are allergic to corticosteroids should therefore be able to cross-react with corticosteroids. Four groups of corticosteroids are recognized both these substances. (A ± D), where substances from the same group may cross-react. In order to investigate the potential cross-reactivity pattern We investigated the potential cross-reactivity pattern and dose- and dose-response relationship, a study was undertaken, in response relationship for several corticosteroids from group A. which patients allergic to tixocortol pivalate were patch-tested We also included the corresponding aldehyde to hydrocortisone, with other substances from group A. as this degradation product has been proposed to be Recent patch-test results (6) have shown, that positive immunogenic. Eleven patients shown to be allergic to tixocortol patch-test results to the more recently developed methyl- pivalate were patch-tested with several corticosteroids from prednisolone aceponate (MPA) (belonging to group D) group A, as well as with the aldehyde, all in serial dilutions. All correlate signi®cantly (pv0.01) with reactions obtained 11 reacted to both tixocortol pivalate and hydrocortisone. The with group A corticosteroids. We therefore also included dose-response relationship for the corticosteroids tended to be this non-halogenated corticoid diester in the patch-test similar to sensitizers lacking anti-in¯ammatory potential.
    [Show full text]